FDA Publishes 17 Revised Draft Guidances for Generic Peptide Products
The FDA has issued new generic peptide guidance, publishing 17 revised draft product-specific guidances (PSGs) for peptide products on July 28, 2026. The documents describe the agency’s current recommendations for how a proposed generic version of certain peptide drugs could be developed and evaluated. They are drafts and are open to public comment.
What the FDA published
The revised draft PSGs cover reference peptide products in several therapeutic areas. According to the FDA’s announcement and the accompanying Federal Register notice, the guidances update the agency’s recommendations across five areas: submission of recombinantly, synthetically, or semi-synthetically produced peptides as abbreviated new drug applications (ANDAs); impurity thresholds; innate immune response (endotoxin-related) testing; higher order structure assessment; and biological activity assessment. As part of the update, the FDA withdrew its May 2021 guidance on ANDAs for certain highly purified synthetic peptide products, stating it no longer reflects the agency’s current scientific thinking.
What “draft guidance” means
Product-specific guidances describe what the FDA currently recommends a developer show to support a generic application; they are not approvals and do not indicate that any generic peptide product is approved or imminent. Because these versions are drafts, the FDA is accepting comments before finalizing them, with a comment period running into late September 2026. The recommendations can change before they are finalized.
Why the quality themes are familiar
Several of the areas the guidances address — impurity limits, endotoxin testing, and confirmation of structure — are the same quality concepts that appear on a peptide Certificate of Analysis. Purity, identity, and endotoxin are distinct measurements, and the FDA’s framework treats them as separate questions rather than a single “quality” number. The guidances sit alongside a broader wave of U.S. regulatory activity on peptides, including the recent advisory-committee vote on peptides for 503A compounding.
VialHelp will continue to summarize FDA actions on peptide quality and regulation as they are published.
